Gavi, the Vaccine Alliance appointed Euro Health Group (EHG) to conduct a mid-term evaluation on the implementation of Gavi’s 2021–2025 strategy (Gavi 5.0/5.1).

In June 2024, Gavi launched the African Vaccine Manufacturing Accelerator (AVMA), a financing instrument that will make up to US$ 1.2 billion available over ten years to support the sustainable growth of Africa’s manufacturing base.

In close collaboration with Vaccine Alliance partners, Gavi has identified vaccine markets where opportunities exist to strengthen global market health. 

Gavi support to drive New Vaccine Introductions by addressing relevant…

In December 2022, the Gavi Board approved a regional manufacturing strategy to support strengthening vaccine supply resilience at regional levels. 

A funding mechanism providing grants for CSOs working to reach zero-dose children and missed communities. Find out how to apply, what types of grants are available, eligibility criteria and countries with calls for proposals.

Communications and social media toolkit, 12 July 2024. This communications toolkit is publically available – feel free to share the link. Partners are encouraged to publish content directly on their platforms.

Access all of the communication and social media toolkits related to the work of the Vaccine Alliance.

A funding mechanism providing grants for CSOs working to reach zero-dose children and missed communities.

With drug-resistant bacterial infections causing an estimated 1.27 million deaths per year globally, antimicrobial resistance (AMR) is an urgent global health challenge. This insight paper elucidates the role of immunisation in mitigating AMR,…

The Gavi 5.0/5.1 learning priorities (LPs) are a set of questions that respond to the Gavi 5.0/5.1 strategy shifts and have clear use cases, for example to influence policies or programmes. The development of LPs began in 2019 with discussions…